Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of the ipilimumab expanded access program

Cancer Investigation

Volumn 32, Issue 4, 2014, Pages 144-149

  Ascierto, Paolo Antonio ^a   Simeone, Ester ^a   Sileni, Vanna Chiarion ^b   Vecchio, Michele Del ^c   Marchetti, Paolo ^d,e   Cappellini, Gian Carlo Antonini ^d   Ridolfi, Ruggero ^f   De Rosa, Francesco ^f   Cognetti, Francesco ^g   Ferraresi, Virginia ^g   Testori, Alessandro ^h   Queirolo, Paola ⁱ   Bernengo, Maria Grazia ^j   Guida, Michele ^k   Galli, Luca ^l   Mandalà, Mario ^m   Cimminiello, Carolina ⁿ   Rinaldi, Gaetana ^o   Carnevale Schianca, Fabrizio ^p   Maio, Michele ^q  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Immunotherapy Unit Romagna National Cancer Institute   (Italy)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j Division of Nuclear Medicine 2   (Italy)

^k NATIONAL CANCER CENTRE   (Italy)

^l UNIVERSITY OF PISA   (Italy)

^m PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

^o UNIVERSITY OF PALERMO   (Italy)

^p Institute of Cancer Research and Treatment Piedmont Oncology Foundation   (Italy)

^q UNIVERSITY HOSPITAL OF SIENA   (Italy)

more..

Author keywords

Cutaneous melanoma; Molecular biology; Treatment; Tumor immunology

Indexed keywords

B RAF KINASE; DABRAFENIB; IPILIMUMAB; LACTATE DEHYDROGENASE; VEMURAFENIB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COHORT ANALYSIS; COMPASSIONATE USE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; ITALY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INDOLES; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898729758     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2014.885984     Document Type: Article

References (24)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, EggermontAM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van Den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
3. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
4. Sznol M, Kluger HM, Hodi FS, McDermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, Puzanov I, Smith DC, Wigginton JM, Kollia G, Gupta AK, Sosman JA. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013;31(Suppl): Abstract CRA9006'.
5. Ribas A, Robert C, Daud A, Hodi FS, Wolchok JD, KeffordR, Patnaik A, Hwu W-J, Weber JS, Joshua A, Hersey P, Gangadhar TC, Joseph RW, Dronca RS, Zarour HM, Ebbinghaus S, Gergich K, Li XN, Kang SP, Hamid O. Clinical efficacy and safety of lambrolizumab (MK-3475, anti-PD-1 monoclonal antibody) in patients with advanced melanoma. J Clin Oncol 2013;31(Suppl): Abstract 9009.
6. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, PetersM, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-256.
7. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of theMEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-489.
8. Flaherty KT, Puzanov I, Kim KB, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, LongGV, GardnerOS, OuelletD, Xu Y, DeMariniDJ, Le NT, Patel K, Lewis KD. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
9. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to BRAF( V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
10. Wagle N, Emery C, BergerMF, DavisMJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-3096.
11. Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N.Do BRAF inhibitors select for populations with disease progression kinetics? J Transl Med 2013;11:61.
12. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013;14:e60-e69.
13. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
14. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-2047.
15. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Chen TT, Berman DM, Wolchok JD. Pooled analysis of longtermsurvival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 2013;49(Suppl 2): Abstract 24LBA.
16. Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day S, Chin KM, McDowell DO, Cykowski L, McHenry B, Wolchok JD. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. J Clin Oncol 2013;31(Suppl): Abstract 9053.
17. Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2013;2:e24320.
18. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, MozzilloN. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithm for clinical use. J Transl Med 2012;10:107.
19. Ribas A, Hodi FS, CallahanM, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-1366.
20. Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, Hodi FS, Ibrahim N, Atkins MB, Cho DC, Sullivan RJ. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. J Clin Oncol 2012;30(Suppl): Abstract 8569.
21. Fisher R, Ali Z, Edmonds K, Turajlic S, Gore M, Larkin J. Clinical behaviour of metastatic melanoma after progression on vemurafenib. Pigment Cell Melanoma Res 2012;25: Abstract 856.
22. ZebolrafTM Summary of Product Characteristics. Available at: Http://www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/002409/WC500124317.pdf. Accessed 2013.
23. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, FollmannM, Frerich B, GantenMK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D. Malignantmelanoma S3-guideline 'diagnosis, therapy and followup of melanoma'. J Dtsch Dermatol Ges 2013;11(Suppl 6):1-116, 1-126.
24. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, MihmMC Jr, Morton DL, RossMI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.